Abstract 39P
Background
Breast cancer (BC) is the most frequently diagnosed cancer among women. Mortality associated with BC is generally attributable to metastatic relapse, which swiftly leads to multi-organ failure. Recent advancements in translational medicine have concentrated on identifying novel biomarkers that can provide valuable insights into patient outcomes. A comprehensive analysis of circulating miRNAs can significantly enhance our understanding of tumorigenesis and facilitate the development of miRNA-based approaches for the prognosis, diagnosis, and treatment of breast cancer.
Methods
21 plasma samples from BC patients were analyzed. Total RNA was extracted in automation and library preparation was carried out with the QIAseq miRNA Library kit (Qiagen). The molecular characterization of circulating miRNAs was performed by massive sequencing on an Illumina miSeq platform. Differential miRNA expression was conducted by the RNA-seq Analysis Portal (RAP) considering as significance a False Discovery Rate (FDR) value <0.1. NGS data were confirmed by RT-qPCR in 30 patients.
Results
The study revealed the aberrant expression of 10 miRNAs between early breast cancer vs metastatic patients. In particular, miR-146a-5p, miR-126-5p, miR-122-5p, miR-16-5p, miR-142-3p, miR-223-3p, miR-103a-3p, miR-221-3p, miR-21-5p, miR-30d-5p were significantly (FDR<0.07) associated with an advanced disease. Likewise, higher levels of miR223-3p, miR146a-5p and miR148b-3p were observed in ductal vs lobular (FDR<0.1) tumor histotypes. The deregulation of one key miRNA correlated with patients’ metastatic pattern. The up regulation of miR126-3p was associated with the development of visceral metastases (FDR<0.05). The expression profiles found are useful in stratify patients in more homogenous groups.
Conclusions
The results of the present study suggest that miRNA profiling could be used as new potential prognostic and predicting tool in breast cancer, overcoming the limitations of the validated biomarkers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Institute of Pathological Anatomy, Universal Hospital of Udine ASUFC, Udine, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Feasibility of digital spatial profiling as a diagnostic: Comparison to immunohistochemistry (IHC)
Presenter: Hannah Hibbs
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
Presenter: Juan Francisco Grau-Béjar
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Analytical validation of a small amplicon NGS panel for MSI detection
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Clinical significance of TROP2 expression in lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - PTEN/CREBBP/NOTCH1 co-alterations with TP53/RB1 define molecular subtypes associated with primary therapy resistance in small cell lung cancer (SCLC)
Presenter: Louisa Hempel
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Role of suppressor of cytokine signalling 6 (SOCS6) in colorectal cancer pathogenesis: Integrating clinical and molecular perspectives
Presenter: Asma Al- Bahri
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases
Presenter: Jan Hojný
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical evaluation cancer testis antigen 45 (CT45) expression in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)
Presenter: David Halafyan
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - A prognostic signature to predict recurrence in patients with residual disease in triple-negative breast cancer: NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract